• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    1/11/24 12:31:07 PM ET
    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    Gainers

    • Atreca (NASDAQ:BCEL) shares increased by 102.7% to $0.22 during Thursday's regular session. The company's market cap stands at $8.6 million.
    • Sagimet Biosciences (NASDAQ:SGMT) stock rose 36.13% to $7.12. The company's market cap stands at $163.0 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares increased by 19.89% to $4.4. The market value of their outstanding shares is at $10.7 million.
    • Galera Therapeutics (NASDAQ:GRTX) stock moved upwards by 14.48% to $0.22. The market value of their outstanding shares is at $12.0 million.
    • Sera Prognostics (NASDAQ:SERA) stock rose 14.45% to $5.78. The company's market cap stands at $181.1 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCCP) shares increased by 13.12% to $20.25.

    Losers

    • 180 Life Sciences (NASDAQ:ATNF) shares declined by 26.7% to $0.22 during Thursday's regular session. The market value of their outstanding shares is at $2.2 million.
    • Cytokinetics (NASDAQ:CYTK) stock declined by 23.15% to $78.11. The company's market cap stands at $7.6 billion.
    • Evoke Pharma (NASDAQ:EVOK) shares declined by 20.18% to $0.75. The market value of their outstanding shares is at $2.5 million.
    • cbdMD (AMEX:YCBD) shares declined by 16.31% to $0.86. The company's market cap stands at $2.5 million.
    • Omega Therapeutics (NASDAQ:OMGA) stock declined by 14.49% to $4.31. The market value of their outstanding shares is at $237.6 million.
    • Edgewise Therapeutics (NASDAQ:EWTX) shares declined by 13.06% to $9.66. The market value of their outstanding shares is at $613.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $BCEL
    $CYCN
    $CYTK

    CompanyDatePrice TargetRatingAnalyst
    Sagimet Biosciences Inc.
    $SGMT
    2/3/2026$27.00Buy
    Guggenheim
    Sagimet Biosciences Inc.
    $SGMT
    1/28/2026$8.00Equal Weight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    12/18/2025$95.00Neutral → Buy
    Goldman
    Sera Prognostics Inc.
    $SERA
    12/15/2025$5.00Buy
    Jefferies
    Edgewise Therapeutics Inc.
    $EWTX
    9/25/2025$20.00Neutral
    Goldman
    Sagimet Biosciences Inc.
    $SGMT
    8/11/2025$28.00Outperform
    Wedbush
    Sagimet Biosciences Inc.
    $SGMT
    8/7/2025$29.00Buy
    H.C. Wainwright
    More analyst ratings

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Sagimet Biosciences with a new price target

    Guggenheim initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $27.00

    2/3/26 7:59:13 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Sagimet Biosciences with a new price target

    Barclays initiated coverage of Sagimet Biosciences with a rating of Equal Weight and set a new price target of $8.00

    1/28/26 7:18:50 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Cytokinetics with a new price target

    Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00

    1/28/26 7:16:37 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

    Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, exclusive license to TAPI's innovative forms of resmetirom active pharmaceutical ingredients (API) First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis China's National Medical Products Administration (NMPA) accepted Ascletis' New Drug Application (NDA) for denifanstat for the

    3/11/26 7:30:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

    –The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –– Data reinforce prior clinical findings of sevasemten in Becker, a rare disease with no approved treatments ––The GRAND CANYON placebo-controlled pivotal cohort is on track to readout in 4Q 2026 –BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy (Becker), a devastating genetic di

    3/10/26 7:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

    SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    3/4/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    SEC Filings

    View All

    SEC Form S-8 filed by Sagimet Biosciences Inc.

    S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)

    3/11/26 8:00:06 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Sagimet Biosciences Inc.

    S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)

    3/11/26 7:58:48 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

    3/11/26 7:41:52 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cytokinetics Incorporated

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/10/26 6:05:24 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cytokinetics Incorporated

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/10/26 6:03:12 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cytokinetics Incorporated

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/10/26 6:00:51 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:04:59 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/4/25 7:42:30 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/4/25 7:33:31 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

    SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    3/4/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

    MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance. "The fourth qu

    2/24/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ATNF
    $BCEL
    $CYCN
    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 6:22:11 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care